Compare Ford Motor Company (F) vs GSK plc (GSK) Price & Performance

Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.

Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.

GSK trades at $52.96, up 1.51% today, with strong technical momentum showing bullish moving averages and neutral oscillators. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $1.36 beating estimates by 7%. Recent FDA approval for Jideytro lung cancer therapy and a $2.52 billion cost-saving initiative support growth prospects. Valuation metrics remain reasonable with P/E of 16.69 and EV/EBITDA of 9.68.

GSK presents a balanced investment case with solid fundamentals and pipeline progress offset by margin pressure risks. The company's 29.73% ROE and consistent dividend payments provide shareholder value, while competitive pressures and patent expirations require careful monitoring. Analyst consensus leans Hold (55%) with 31% Buy ratings, suggesting cautious optimism for the pharmaceutical giant's transformation under new leadership.